Media

News Releases

Teva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE® 40mg/mL by Health Canada

23/08/16

Montreal, Quebec – August 23, 2016 – Teva Canada Innovation, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved three-times-a-week COPAXONE® (glatiramer acetate) 40 mg/mL injection. This new formulation of COPAXONE® will allow for a less frequent dosing regimen for patients with relapsing remitting multiple sclerosis (RRMS). In addition to the newly approved dose, daily COPAXONE® 20 mg/mL will continue to be available.

Read more here

News Releases

Teva Canada Innovation Announces Approval of CINQAIR(TM) by Health Canada

25/07/16

Montreal, Quebec – July 25, 2016 – Teva Canada Innovation, a subsidiary of Teva Pharmaceutical Industries Ltd., announced today that Health Canada has approved CINQAIR(TM) (reslizumab), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), for the add-on maintenance treatment of adult patients with severe eosinophilic asthma who are inadequately controlled with medium-to-high-dose inhaled corticosteroids and an additional asthma controller(s) (e.g. LABA), and have a blood eosinophil count of ≥400 cells/μL at initiation of the treatment.

Read more here